Европейский союз - хорватский - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cjepiva - active immunisation against h5 subtype of influenza a virus.

Черногория - хорватский - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

dio stranog druŠtva "sanofi - aventis" - podgorica - vakcina protiv hepatitisa a (inaktivisana, adsorbovana) - suspenzija za injekciju u napunjenom injekcionom špricu - 160 antigen j./0.5ml

Европейский союз - хорватский - EMA (European Medicines Agency)

seqirus gmbh - virus gripe površinskih antigena (гемагглютинина i нейраминидазы), инактивированная, od sljedećih sojeva:a/california/7/2009 (Н1n1)pdm09 - takav soj(a/brisbane/10/2010, divlji tip)a/Švicarska/9715293/2013 (Н3n2) - kao što su soja(a/južna australija/55/2014, divlji tip)b/phuket/3073/2013–kao i deformacija(b/utah/9/2014, divlji tip) - influenza, human; immunization - cjepiva - profilaksa gripe za odrasle osobe, osobito kod onih koji povećuju rizik od povezanih komplikacija. optaflu mora se koristiti u skladu sa službenim vodstvom.

Европейский союз - хорватский - EMA (European Medicines Agency)

intervet international b.v. - svinjske цирковирус tipa 2 (pcv2) podjedinica antigen orf2, микоплазмы hyopneumoniae soja j инактивированная - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinja (za tov) - za aktivne imunizacije svinja za smanjenje виремии, virusne opterećenje u pluća i лимфоидных tkivima, izlučivanje virusa uzrokovana svinjske цирковирус tipa 2 (pcv2) infekcije i težini lezije pluća uzrokovane mycoplasma hyopneumoniae infekcije. kako bi se smanjio gubitak dnevne debljanja tijekom razdoblja završetka u lice infekcija s mycoplasma hyopneumoniae i / ili pcv2 (kao što je vidljivo u terenskim studijama).

Европейский союз - хорватский - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigeni virusa influence (hemaglutinin i neuraminidaza) soja a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

sanofi pasteur, 14 espace henry vallee, lyon, francuska - toksoid difterije toksoid tetanusa toksoid hripavca filamentozni hemaglutinin hripavca pertaktin hripavca fimbrijalni aglutinogeni hripavca 2 i 3 poliovirus tip 1, soj mahoney (inaktiviran) poliovirus tip 2, soj mef-1 (inaktiviran) poliovirus tip 3, soj saukett (inaktiviran) - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: 1 doza (0,5 ml) sadrži: ≥ 2 iu (2 lf) toksoida difterije, ≥ 20 iu (5 lf) toksoida tetanusa, 2,5 mikrograma toksoida hripavca, 5 mikrograma filamentoznog hemaglutinina, 3 mikrograma pertaktina, 5 mikrograma fimbrija tipa 2 i 3, viruse polimijelitisa (inaktivirane, proizvedene u vero stanicama): 29 d antigen jedinica - tip 1 (mahoney), 7 d antigen jedinica - tip 2 (mef-1), 26 d antigen jedinica - tip 3 (saukett); adsorbirane na 1,5 mg aluminijeva fosfata (0,33 mg al3+)

Европейский союз - хорватский - EMA (European Medicines Agency)

intervet international b.v. - svinjski circovirus tip 2 orf2 podjedinica antigena - immunologicals for suidae, inactivated viral vaccines - svinje - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

Европейский союз - хорватский - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - cjepiva protiv gripe - profilakcija influence uzrokovana virusom a (h1n1v) 2009. focetria mora se koristiti u skladu sa službenim vodstvom.

Европейский союз - хорватский - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Европейский союз - хорватский - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.